

Fra: "Beredskap Hdir"
Sendt: fredag 7. august 2020 06:22:57
Til: "Beredskap Hdir" <Beredskap.Hdir@helsedir.no>
Emne: VS: nytt oppdrag nr 133-Bistand til å svare ut forespørsel fra Turkmenistan
Vedlegg: Svar: Nytt oppdrag nr 133-Bistand til å svare ut forespørsel fra Turkmenistan

Fra: Beredskap Hdir
Sendt: torsdag 6. august 2020 18:03
Til: 'Dahl Per Gunnar' <Per-Gunnar.Dahl@hod.dep.no>
Kopi: HOD-Krisestab_NY <Krisestab_NY@hod.dep.no>; Nordeng Guro Lindland <Guro-Lindland.Nordeng@hod.dep.no>; Tysse Anders Lamark <Anders-Lamark.Tysse@hod.dep.no>; Wroldsen Tone <Tone.Wroldsen@hod.dep.no>; Thoresen Nina Horg <Nina-Horg.Thoresen@hod.dep.no>; Steinar Olsen <Steinar.Olsen@helsedir.no>; Helsekrise <Helsekrise@helsedir.no>; smittevern <smittevern@helsedir.no>; Andreas Skulberg <Andreas.Skulberg@helsedir.no>
Emne: SV: nytt oppdrag nr 133-Bistand til å svare ut forespørsel fra Turkmenistan

Hei
Vedlagt innspill fra CBRNE- senteret på tekst knyttet til forespørselen fra Turkmenistan

Vh
Rune Arnesen
Beredskapsstab
Helsedirektoratet

Fra: Dahl Per Gunnar <Per-Gunnar.Dahl@hod.dep.no>
Sendt: fredag 31. juli 2020 10:54
Til: Beredskap Hdir <beredskap@helsedir.no>
Kopi: HOD-Krisestab_NY <Krisestab_NY@hod.dep.no>; Nordeng Guro Lindland <Guro-Lindland.Nordeng@hod.dep.no>; Tysse Anders Lamark <Anders-Lamark.Tysse@hod.dep.no>; Wroldsen Tone <Tone.Wroldsen@hod.dep.no>; Thoresen Nina Horg <Nina-Horg.Thoresen@hod.dep.no>
Emne: nytt oppdrag nr 133-Bistand til å svare ut forespørsel fra Turkmenistan

Motta nytt oppdrag nr 133

Frist er onsdag 5. august.

Oppdrag:

HOD Ber Helsedirektoratet om å kvalitetssikre utkast til svar på spørsmål fra Turkmenistan's ambassade i Storbritannia.

Turkmenistan spør om følgende:

"We are currently studying the experience of other countries in the methods of treating coronavirus.

In this regard we would appreciate if you could share with the available information about the methods of treatment of coronavirus, particularly the most actively used medicines in Norway (remdesivir, avifavir / avigan, dexamethasone, camostat, etc.) or combination-protocols for the treatment of different complexity of the disease and also a non-drug methodology for the prevention and treatment of the disease for further transmission of this information to Turkmenistan. Or perhaps you can direct us to the relevant authority in this matter to obtain the information.

Also, if possible we would like to ask you for any information about where and how medicines and necessary medical equipment can be purchased from and / or the possibility of manufacturing inside in the country."

Utkast til svar

There is currently no established specific treatment for covid-19 infection in Norway. The general treatment is antipyretic drugs and oxygen supply as needed, as well as intravenous fluid therapy as needed. Critically ill people in the intensive care unit may need respirator treatment. <https://oslo-universitetssykehus.no/behandlinger/covid-19>

The Norwegian Medicines Agency, in cooperation with clinical experts, has prepared a list of medicines that may be required in the supportive treatment and treatment of comorbidities in patients with covid-19:

<https://legemiddelverket.no/import-og-salg/import-og-grossistvirksomhet/viktige-legemidler-til-stottebehandling-i-forbindelse-med-covid-19>

All experimental drug treatment for covid-19 infection should preferably take place within the framework of clinical trials, and many Norwegian hospitals are participating in the WHO Solidarity clinical trial:

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments>

The Norwegian Hospital Procurement Trust (Sykehusinnkjøp HF <https://sykehusinnkjop.no/>) is responsible for procuring e.g. pharmaceuticals for the specialised health service in general, and during covid-19 also assist the entire Norwegian health service in procuring personal infection control equipment and medicines for health trusts (hospitals) and the municipal health and care service.

Norwegian Medicines Agency has conducted a mapping of production capacity in Norway. You can read more about this here: <https://legemiddelverket.no/nyheter/legemiddelproduksjon-i-norge-hva-er-mulig> (Norwegian only)

You may also find more information from The Norwegian Medicines Agency about covid-19 and medicines here (in English):

<https://legemiddelverket.no/english/covid-19-and-medicines/development-of-medicines-and-vaccines-against-covid-19>

<https://legemiddelverket.no/english/covid-19-and-medicines>

General information about covid-19 in English:

<https://www.regjeringen.no/en/topics/koronavirus-covid-19/id2692388/>

<https://www.fhi.no/en/id/infectious-diseases/coronavirus/>

<https://helsenorge.no/coronavirus>

<https://www.helsedirektoratet.no/english/corona>

HOD vil videreformidle svar til UD, som svarer ut ambassaden.

Vi ber om at svar sendes til Anders L. Tysse: alt@hod.dep.no med kopi til Tone Wroldsen: towr@hod.dep.no og HOD-Krisestab_NY Krisestab_NY@hod.dep.no



Per Gunnar Dahl

Seniorrådgiver

Helse- og omsorgsdepartementet

Mobil: 94167016

HOD Krisestab

Vakttelefon HOD 22 24 47 77

Vakt-covid19@hod.dep.no